ArriVent BioPharma, Inc..
AVBP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs in oncology. The company's pipeline includes novel therapies targeting various cancer types. ArriVent BioPhar...Show More
Better Health for All
20
ArriVent BioPharma's core business is entirely devoted to developing innovative medicines for oncology, addressing significant unmet medical needs in cancer types such as NSCLC, GI cancers, and solid tumors.
1
This aligns with the company's entire business being devoted to health improvement, with its products delivering exceptional health benefits. The company has no products with significant negative health impacts, as its focus is solely on therapeutic development. All of the company's R&D budget is dedicated to health improvement through its multiple drug development programs in various clinical phases and partnerships.
2
The company's operations do not involve nutrition, food safety, or products with addiction potential, making these KPIs not applicable.
3
As a clinical-stage biopharmaceutical company, its primary activity involves clinical trials, and while no specific details on ethical conduct are provided,
4
the nature of its business means this KPI is applicable, and without negative evidence, it defaults to neutral.
Fair Money & Economic Opportunity
0
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines.
1
The provided articles detail its drug pipeline, partnerships, regulatory designations, and public stock offerings. There is no evidence that the company engages in activities related to lending, insuring, moving, or storing money, or offers any financial products or services to consumers. Therefore, all KPIs related to Fair Money & Economic Opportunity are not applicable to the company's core business as evidenced.
Fair Pay & Worker Respect
0
No evidence available to assess ArriVent BioPharma, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess ArriVent BioPharma, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
The company restated its financial statements for the year ended December 31, 2022, due to material weaknesses in internal control over financial reporting related to the review and approval of manual journal entries and accounting for certain nonroutine transactions.
1
These weaknesses were remediated as of December 31, 2024.
2
A formal whistleblower policy, effective January 26, 2024, includes a 24/7 anonymous hotline and an anti-retaliation pledge.
3
The company states it will implement a training program and audit compliance with the Code of Conduct.
4
All board members, except for two, are independent directors.
5
The company has a publicly available Code of Conduct and Ethics and Whistleblower Policy, effective January 26, 2024, which includes an anti-corruption policy prohibiting bribery and addressing FCPA compliance, with a training program planned for associates.
6
Kind to Animals
-40
The company's operations involve preclinical and nonclinical studies, and it acknowledges the need to obtain animals or materials to generate in vivo data to support clinical trials.
1
The FDA and comparable foreign regulatory authorities enforce GLP requirements for nonclinical studies and may require additional preclinical or nonclinical studies.
2
This indicates that animal testing is a part of its drug development process, primarily driven by legal mandates. There is no evidence of a company policy that articulates a reduction intent, consistent enforcement, or reporting on animal testing beyond regulatory requirements.
3
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess ArriVent BioPharma, Inc. against any of the 'No War, No Weapons' KPIs. The articles discuss general export controls on laboratory instruments and biotechnology products with dual-use potential, but they do not state that ArriVent BioPharma, Inc. develops, invests in R&D for, manufactures, or sells these specific dual-use technologies or AI systems with military applications.
1
One article explicitly states that sustainability data for AVBP.US is unavailable.
2
Therefore, no KPIs could be scored.
Planet-Friendly Business
0
No specific, concrete data points for AVBP.US were found across any of the provided articles for any of the Planet-Friendly Business KPIs. The articles either explicitly state 'No sustainability data is available for AVBP.US'
1
or discuss general industry trends and challenges without providing company-specific performance metrics.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding ArriVent BioPharma, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles primarily consist of promotional material for a data software company or general information about ArriVent BioPharma's drug development activities, explicitly stating a lack of relevant data for this assessment.
Safe & Smart Tech
-10
ArriVent BioPharma, Inc. has reported no material cybersecurity incidents in the last three fiscal years.
1
The company states it deploys strict encryption across all computer systems, networks, websites, mobile apps, offices, and stores.
2
It conducts regular cybersecurity training for employees and contractors, including phishing simulations.
3
The company has established procedures for managing cybersecurity risk, strategy, and governance, with oversight from its audit committee.
4
ArriVent implements access controls to its information technology and conducts vulnerability assessments, penetration testing, and threat modeling.
5
The company's privacy policy outlines user rights to access, rectify, erase, restrict processing, data portability, and object to personal data processing.
6
ArriVent collects only necessary personal data and has retention periods ranging from 1 year for website users to 25 years for clinical trial data.
7
The company states it complies with Data Protection Legislation in the UK and EU, including GDPR, and EU Clinical Trial Regulations.
8
However, the company's privacy policy indicates that privacy considerations are integrated into the development process, but a retention schedule is followed, which is a basic aspect of privacy by design rather than a comprehensive integration. The company does not intend to conduct automated decision-making for personal data.
9
Zero Waste & Sustainable Products
0
No specific, concrete data or initiatives for ArriVent BioPharma, Inc. (AVBP.US) regarding zero waste and sustainable products were found in the provided articles.
1
The articles discuss general industry trends, challenges, and initiatives by other companies, but do not offer any company-specific metrics, targets, or performance data for AVBP.US across any of the KPIs.
2